The diagnosis and management of parasellar tumours of the pituitary

REVIEWEndocrine-Related Cancer (2008) 15 885–903

The diagnosis and management ofparasellar tumours of the pituitary

Gregory A Kaltsas, Jane Evanson1, Alexandra Chrisoulidou 2

and Ashley B Grossman3

Endocrine Unit, Department of Pathophysiology, National University of Athens, Athens, Greece1Department of Academic Radiology, St Bartholomew’s Hospital, London, UK2Department of Endocrinology, Theagenion Hospital, Thessaloniki, Greece3Department of Endocrinology, St Bartholomew’s Hospital, London EC1A 7BE, UK

(Correspondence should be addressed to A B Grossman; Email: [email protected])

Abstract

The sellar and parasellar region is an anatomically complex area where a number of neoplastic,inflammatory, infectious, developmental and vascular diseases can develop. Although most sellarlesions are due to pituitary adenomas, a number of other pathologies involving the parasellarregion can present in a similar manner. The diagnosis of such lesions involves a multidisciplinaryapproach, and detailed endocrinological, ophthalmological, neuroimaging, neurological and finallyhistological studies are required. Correct diagnosis prior to any intervention is essential as thetreatment of choice will be different for each disorder, particularly in the case of primary malignantparasellar tumours. The complexity of structures that define the parasellar region can produce avariety of neoplastic processes, the malignant potential of which relies on histological grading. Inthe majority of parasellar tumours, a multimodal therapeutic approach is frequently necessaryincluding surgery, radiotherapy, primary or adjuvant medical treatment and replacement ofapparent endocrine deficits. Disease-specific medical therapies are mandatory in order to preventrecurrence or further tumour growth. This is particularly important as neoplastic lesions of theparasellar region tend to recur after prolonged follow-up, even when optimally treated. Apart fromthe type of treatment, identification of clinical and radiological features that could predict patientswith different prognosis seems necessary in order to identify high-risk patients. Due to their rarity,central registration of parasellar tumours is required in order to be able to provide evidence-baseddiagnostic and mainly therapeutic approaches.

Endocrine-Related Cancer (2008) 15 885–903

Introduction

The area immediately around the pituitary, the sellar

and parasellar region, is an anatomically complex area

that represents a crucial crossroads for important

adjacent structures (Ruscalleda 2005). While the sellar

region has specific anatomical landmarks, the para-

sellar region is not clearly delineated and includes all

the structures that surround the sella turcica (Rennert &

Doerfler 2007). Vital structures such as the brain

parenchyma, meninges, visual pathways and other

cranial nerves, major blood vessels, hypothalamo-

pituitary system (HPS) and bony compartments may be

involved. A diversity of clinical symptoms and signs

can develop from a number of neoplastic, inflam-

matory, infectious, developmental and vascular


1351–0088/08/015–885 q 2008 Society for Endocrinology Printed in Great

diseases that occupy the parasellar area secondary to

the location, size and growth potential of the lesions,

and the subsequent damage to specific adjacent vital

structures (Freda & Post 1999).

Pituitary adenomas are the most common cause of a

sellar mass extending to the parasellar region (Freda &

Post 1999). However, in w9% of cases, an aetiology

other than a pituitary adenoma is encountered, para-

sellar tumours being the second commonest cause after

non-tumorous cystic lesions (Freda et al. 1996). The

malignant potential of these tumours may be defined

according to the World Health Organization (WHO)

classification of tumours of the central nervous system

(CNS), which relies on histological criteria: WHO

grade I (tumours with low proliferative potential and

the possibility of cure following surgical resection),

Britain

DOI: 10.1677/ERC-08-0170

Online version via http://www.endocrinology-journals.org

http://dx.doi.org/10.1677/ERC-08-0170

G A Kaltsas et al.: Parasellar tumours

WHO grade II (infiltrative tumours with low mitotic

activity that can recur and progress to higher grades of

malignancy),WHO grade III (tumours with histological

evidence ofmalignancy) andWHOgrade IV (mitotically

active tumours with rapid evolution of disease; Kleihues

et al. 1993). The latest version of theWHOclassification,

including somenewhistologically identified variants that

may have some clinical relevance, has recently been

published (Louis et al. 2007). A number of other non-

neoplastic lesions, such as inflammatory, granulomatous,

infectious and/or vascular pathologies can also involve

the parasellar region (Table 1).

In this paper, we primarily attempt an overview of

the clinical, endocrine and radiological features of

Table 1 Classification of parasellar tumours according to

malignant potential and other parasellar lesions

Malignant parasellar tumours

Gliomas

Germ cell tumours

Primary lymphomas

Metastases

Supratentorial primitive neuroectodermal tumours (PNET)

Ependymoblastomas

Potentially malignant parasellar tumours (low-grade

malignant tumours)

Craniopharyngiomas

Chordomas/chondrosarcomas

Haemangiopericytomas

Langerhans’ cell histiocytosis (LCH)

Benign parasellar tumours

Meningiomas (except rare atypical and anaplastic

meningiomas)

Rathke’s cyst

Epidermoids/dermoids

Hamartomas

Paragangliomas

Lipomas

Neurinomas/Schwannomas

Parasellar granular cell tumours

Ganglion cell tumours

Non-neoplastic pathologies of the parasellar region

Granulomatous, infectious and inflammatory lesions

Pituitary abscess, bacterial and fungal

Tuberculosis

Sarcoidosis

Wegener’s granulomatosis

Mucocele (sphenoid)

Hypophysitis (lymphocytic, granulomatous, xanthomatous)

Tolosa–Hunt syndrome

Vascular lesions

Aneurysms

Cavernous sinus thrombosis

Pituitary apoplexy

Miscallaneous (CSF related)

Empty sella syndrome

Arachnoid cyst

Suprasellar-chiasmatic arachnoiditis

886

neoplastic parasellar tumours, taking into consider-

ation their malignant potential (Table 1). In addition,

currently available therapeutic schemes and the long-

term prognosis of these tumours will also be discussed.

Non-neoplastic parasellar lesions will also be briefly

mentioned but not discussed into detail.

Anatomical considerations

The parasellar region includes, laterally, the dural

walls of the cavernous sinus, a multi-lobulated venous

structure containing the intracavernous portion of the

internal carotid artery, cranial nerves III, IV, VI and the

V1 and V2 branches of the trigeminal nerve (Smith

2005; Fig. 1). The relationships of the cavernous sinus

are: inferiorly with the basisphenoid and sphenoid

sinus; superiorly, the diaphragma sella, with the

suprasellar subarachnoid spaces containing the optic

nerves and chiasm, hypothalamus, tuber cinereum and

anterior third ventricle (Ruscalleda 2005). The naso-

pharynx and the medial aspects of the temporal lobes

are also closely related to the parasellar region; in

addition, embryonal remnants can also be found

contributing further to the diversity of the processes

that are involved in delineating the anatomy of this

region (Smith 2005).

Clinical presentation

Non-pituitary adenomatous parasellar lesions do not

present with hypersecretory syndromes but rather with

hypopituitarism or symptoms of mass effect due to

compression of nearby vital surrounding structures, the

Figure 1 Sagittal enhanced T1-weighted image of a hypo-thalamic glioma. This is partially cystic, partially solid andinvolves the chiasm and the hypothalamus.

www.endocrinology-journals.org


severity of which depends on the location, size and

growth potential of the tumours (Glezer et al. 2008).

Visual loss is a common presenting complaint due to

the proximity of tumours to the optic nerves, chiasm

and optic tracts. Headache develops either as a

consequence of increased intracranial pressure (IP),

distortion of the diaphragma or irritation of the

parasellar dura (Freda & Post 1999). As parasellar

tumours commonly originate or infiltrate structures

within close proximity to the cranial nerves traversing

through the cavernous sinus, cranial nerve abnormal-

ities develop in w25% of cases (Jagannathan et al.

2007). Hypothalamic tumours in children may produce

the diencephalic syndrome manifest as wasting, poor

development and sexual immaturity, whereas in adults

it may lead to disruption of the control of appetite and

cause severe obesity or starvation (Freda & Post 1999).

Involvement of the hypothalamus and pituitary leads to

complete or partial pituitary hormonal deficiencies;

hyperprolactinaemia may also develop secondary to

stalk compression (Glezer et al. 2008). Diabetes

insipidus (DI) is a common finding in parasellar

tumours and indicates that the lesion is unlikely to be

a pituitary adenoma; however, it cannot reliably

distinguish among the various parasellar tumours

(Freda & Post 1999).

Imaging

Radiological imaging of the parasellar region is

challenging since the sella is a small volume region

in close proximity to many complex structures

(Ruscalleda 2005). Both thin-section computerised

tomography (CT) and magnetic resonance imaging

(MRI) play an important role in the anatomical

delineation of lesions in this area (Boardman et al.

2008). MRI is the modality of choice providing

multiplanar high-contrast images, whereas CT has a

complementary role in delineating bony destruction

and the visualisation of calcification (Rennert &

Doerfler 2007). Conventional radiology is no longer

in use, whereas digital subtraction angiography has

been largely replaced by the continuous improvement

in MR and CT angiographies (Rennert & Doerfler

2007). Although the radiological features of parasellar

tumours have many similarities, some may have

distinctive findings (Chong & Newton 1993, Freda &

Post 1999, Ruscalleda 2005, Smith 2005; Table 2).

However, the differential diagnosis among the various

types of tumours remains difficult using currently

available methods of morphological imaging.


Diagnosis

In formulating a management plan, histological

confirmation is usually required unless there are

lesion-specific clinical, endocrine and/or radiological

features. Existing methods of skull base biopsy in the

anatomically critical parasellar region include either

open skull base approaches or image-guided needle

biopsy (Day 2003, Samandouras et al. 2005). Image-

guided techniques may help in diagnosis, but can be

time-consuming and cannot reliably avoid surrounding

critical neurovascular structures; in selected patients

endoscopic transnasal biopsy can be applied (Frighetto

et al. 2003, Samandouras et al. 2005). However, the

use of such methods should be weighed along with the

potential morbidity and mortality of the procedures

when the risk of inducing damage to a vital structure is

high, while the expected benefit from obtaining the

correct diagnosis may be questionable.

Therapy

Surgery remains the treatment of choice for benign

tumours and malignant tumours that are not responsive

to other forms of treatment, and/or when surgical

debulking is essential (Day 2003, Glezer et al. 2008).

Surgical therapy

Parasellar tumours usually have irregular margins and

adhere to vital neurovascular structures, and thus do

not allow a complete resection without the danger of

affecting critical brain areas (Couldwell et al. 2004).

Resection is attempted by craniotomy and/or trans-

sphenoidally (TSS), particularly for smaller tumours

approachable through the sella (Baskin & Wilson

1986, Honegger et al. 1992). For massive lesions, a

two-stage removal procedure may be necessary;

initially TSS debulking followed by craniotomy later.

This approach may allow residual tumour to descend

inferiorly, facilitating further resection (Maira et al.

1995). Recently, the development of advanced cranial

base TSS approaches has facilitated the exposure of

basal lesions by the removal of osseous structures,

minimising brain retraction and providing safe alterna-

tives when assessing lesions involving the tuberculum

sella, suprasellar region, cavernous sinus or clivus

(Couldwell et al. 2004). The TSS route can also be

used for midline lesions without significant lateral

extension (Day 2003). In cases of hydrocephalus,

resection may be achieved following decompression of

the ventricles and stabilisation of the clinical status of

the patient. In the presence of large cystic lesions, as

with craniopharyngiomas, fluid aspiration can be

887

Table 2 Imaging characteristics of parasellar tumours

Diagnosis CT and/or MRI characteristics

Malignant tumours

Gliomas (hypothalamic or optic pathway) On CT hypo/isodense pre-contrast mass. Variable enhancement on post-contrast

images Rarely calcifications, haemorrhages solid lesions. Occasionally small

cystic or necrotic components in large legions. On MRI hypointense on

T1-weighted images and hyperintense on T2 images. Variable enhancement

following contrast administration

Germ cell tumours On CT, well-delineated masses, usually hyperdense lesions. Most cases show

strong homogenous enhancement. On MRI, isointense on T1-weighted images

and iso- to hyperintense on T2-weighted images

Metastases On MRI, signal intensity varies depending on the primary tumour. Generally

hypointense on T1-weighted images and hyperintense on T2-weighted images

Lymphoma On MRI, slight hypointensity on both T1- and T2-weighted images

Plasmatocytoma On MRI, slight hypointensity on both T1- and T2-weighted images

Potentially malignant tumours

Craniopharyngiomas Calcifications occur in up to 80%, best depicted by CT. Cysts are present in the

majority of craniopharyngiomas that tend to predominate in children containing

highly proteinaceous fluid. The fluid is usually very bright on pre-contrast

T1-weighted MRI. In adults the solid components are larger and the cysts tend

to be small or multiloculated. The solid portions and cyst walls enhance usually

heterogeneously

Chordomas chondrosarcomas On CT, bone destroying mass, centred on the spheno-occipital synchondrosis

with occasional intratumoural calcifications. MR images show a heterogeneous

mass with internal septations and heterogeneous enhancement. Chordomas

are typically midline lesions

Haemangiopericytomas On MRI, hypointense lesions on T1-weighted images and heterogeneously

hyperintense on T2-weighted images

Langerhans’ cell histiocytosis On MRI uniform thickening of the pituitary stalk with homogenous enhancement

of the hypothalamic stalk. Occasionally, solitary nodules may develop in the

HP region

Mostly benign tumours

Meningioma On CT, isodense to slightly hyperdense with dense homogenous enhancement.

Calcification is seen in 20–50%. On MRI appear isointense in both T1- and

T2-weighted images although T2 signal intensity may be more variable. Differ

from pituitary adenomas due to differential uniform enhancing pattern. Majority

exhibit broad dural attachment and show a dural tail on post-contrast imaging

accompanied by bony hyperostosis and normal sellar dimension

Epidermoid cyst On CT lobulated mass with areas of calcification and attenuation values similar to

CSF. On MRI, similar characteristics to CSF without post-contrast enhance-

ment but bright on diffusion scans

Dermoid cyst On CT, round or lobulated with negative density values and foci of calcification.

There is no contrast enhancement or surrounding oedema. On T1-weighted

images, high signal due to lipid content

Hamartoma Pedunculated hypothalamic mass, isodense on CT and MRI, relatively to grey

matter. It does not calcify or enhance following contrast administration

Schwannoma On CT they appear as contrast enhancing masses that follow the course of

involved nerves. On MRI they appear as well-defined masses isointense on

T1-weighted images with strong contrast enhancement; on T2-weighted images

appear isointense to hyperintense

Rathke’s cyst On MRI appear as discrete cystic lesions with variable signal intensity. They

appear to have the density of CSF, with low intensity on T1 and high intensity on

T2-weighted images. Calcification of the cyst is usually absent and this may

help differentiate them from craniopharyngiomas. Contrast enhancement is

rare and when occurs it is confined to the cyst wall

Data derived from the following references: FitzPatrick et al. (1999), Freda & Post (1999), Zee et al. (2003), Ruscalleda (2005), Smith(2005), Karavitaki et al. (2006), Rennert & Doerfler (2007), Glezer et al. (2008) and Jalali et al. (2008).


www.endocrinology-journals.org888


applied first as may provide relief of the obstruction

and facilitate further tumour removal (Karavitaki

et al. 2006).

Radiotherapy (RT)

Conventional RT has traditionally been used either as

primary treatment or as a way to prevent further

tumour growth or recurrence (Brada & Cruickshank

1999, Perks et al. 1999). More sophisticated radio-

therapeutic techniques have recently been introduced.

Stereotactic radiosurgery delivers a single fraction of

high-dose ionising radiation on mapped targets,

keeping the exposure of adjuvant tissues to a minimum

and allowing for the delivery of maximum tolerated

dose of between 10 and 15 Gy (Giller & Berger 2005).

Stereotactic RT combines the accurate focal delivery

of stereotactic radiosurgery with the radiobiological

advances of fractionation; compared with conventional

RT, it minimises long-term toxicities by offering

optimal sparing to surrounding tissue (Tarbell et al.

1994). Robotically controlled frameless radiosurgery

has also been developed and studies assessing its

efficacy are awaited (Giller et al. 2005). In general, RT

seems to be a valuable asset in the treatment of these

tumours, albeit with potential adverse effects to nearby

tissue and the HPS (Brada & Cruickshank 1999).

Medical therapy

Chemotherapy remains the primary therapy for

responsive malignant tumours in either a neoadjuvant

or adjuvant setting following surgery and/or RT.

Patients with infrequently curable or unresectable

tumours should be considered candidates for clinical

trials that evaluate interstitial brachytherapy, radio-

sensitisers, hyperthermia, or intraoperative radiation

therapy in conjunction with external RT to improve

local tumour control. Such patients are also candidates

for studies that evaluate new drugs and biological

response modifiers following RT. Therapy of

established or evolving specific pituitary and hypo-

thalamic hormonal deficits should be detected and

adequately treated (Lamberts et al. 1998). Optimum

hormonal replacement therapy should be aimed for,

although even with replacement therapy parasellar

tumours, particularly craniopharyngiomas, have a

worse prognosis compared with pituitary adenomas

(Tomlinson et al. 2001).

Follow-up

Prognosis is dependent on patient status, comorbid

conditions, tumour size and extension, and the precise


histopathology. Children and adolescents should have

careful monitoring of height, weight and pubertal

status, while a dedicated neuroendocrine team should

screen patients for endocrine and neuropsychological

deficits at regular intervals. Post-operative imaging

should be performed within 3 months of treatment and

generally at 6 and 12 months to evaluate tumour

recurrence or presence of residual tumour.

Malignant tumours of the parasellar region

Gliomas

Gliomas may arise in the hypothalamus, optic chiasm,

nerve or tract (Zee et al. 2003; Fig. 1). The main

histopathological subtype is the pilocytic astrocytoma

(WHO grade I), which is a low-grade malignant lesion

associated occasionally with neurofibromatosis type 1

(NF1; Zee et al. 2003). In this instance, lesions can be

multiple including optic nerve gliomas, low-grade

brain stem gliomas and basal ganglia non-neoplastic

hamartomas (Zee et al. 2003). The remainder of

hypothalamic/optic chiasm lesions are diffuse astro-

cytomas (WHO grade II), representing 35% of all

astrocytic brain tumours (Smith 2005). This type of

tumour typically affects young adults and has a

tendency for malignant progression to anaplastic

astrocytoma and, very rarely, glioblastoma (WHO

grades III–VI). Hypothalamic/chiasmatic astrocytomas

are primarily seen in adulthood presenting with

impaired vision and retro orbital pain (Black & Pikul

1999). In children, they may present with visual loss,

headache, proptosis and the diencephalic syndrome

(Glezer et al. 2008). On imaging, hypothalamic/

chiasmal gliomas are usually large suprasellar masses,

infiltrating the brain and third ventricle, which enhance

homogeneously; rarely, there is necrosis, haemorrhage

or calcification (FitzPatrick et al. 1999). There is

uncertainty as to the optimum therapy, and many can

be simply observed; obviously, visual loss will

determine the need for surgery. The mean survival

time after surgical intervention is between 6 and 8

years, with considerable individual variation (Kitange

et al. 2003). Optic pathway gliomas generally behave

benignly, with very slow growth; however, tumours

around the chiasm/hypothalamus can be more

aggressive, exhibiting a 50% 5-year survival (Kitange

et al. 2003).

Gliomas can also develop in the brainstem and

extend into the parasellar region (Packer 2000,

Guillamo et al. 2001). Diffuse intrinsic low-grade

glioma (WHO grade II) is the most prominent type,

whereas purely malignant brainstem glioma (WHO

grades III–VI) occurs in 31% of cases (Guillamo et al.

889


2001). The median survival of low-grade gliomas is 7.3

years whereas that of high-grade gliomas was 11.2

months (Guillamo et al. 2001). Stereotactic biopsy has

been reported to provide the diagnosis with minimal

morbidity (Packer 2000). Although glucocorticoids

and irradiation may temporarily improve symptoms,

there seems to be no long-term benefit (Recinos et al.

2007). Occasionally, mixed gliomas may occur, for

which temozolomide, an oral derivative of dacarba-

zine, may be useful therapy. Clinical improvement has

been noted in 51% of patients, with a radiological

response rate of 31% (Hoang-Xuan et al. 2004).

Germ cell tumours (GCTs)

Primary intracranial GCTs are neoplasms most

commonly present in the first two decades of life

(Janmohamed et al. 2002; Fig. 2). Like other

extragonadal GCTs, CNS variants develop around the

midline, with 80% arising around the third ventricle,

mostly in the region of the pineal gland, followed by the

suprasellar compartment and anterior hypothalamic

regions (Jennings et al. 1985). Synchronous GCTs at

both these sites are found at w5–10% (Jennings et al.

1985). Germinomatous GCT (GGCT) are the most

exquisitely radiosensitive, whereas non-GGCT

(NGGCT), comprising choriocarcinoma, teratoma,

embryonal sinus (yolk sac) tumour and embryonal

carcinoma, have a poorer overall response to treatment

and aworse prognosis (Allen et al. 1987,Balmaceda et al.

1996). Non-GCT can also contain germinomatous

elements (Calaminus et al. 2005). Pineal GCT classically

give rise to raised IP, hydrocephalus and Parinaud’s

syndrome, whereas suprasellar GCT typically present

with cranial DI, hypopituitarism and visual disturbance,

and may lead to dissemination via the CSF (Legido et al.

Figure 2 Sagittal enhanced T1-weighted image of a germinomawith both a suprasellar and pineal enhancing mass lesions.

890

1989, Janmohamed et al. 2002). Diagnosis is established

by histology but a subgroup can be diagnosed on the basis

of elevation of specific tumour markers (Calaminus et al.

2005), or typical clinical and radiological features. Yolk

sac tumours secrete a-fetoprotein and choriocarcinomas

b-human chorionic gonadotrophin (b-hCG) that can be

detected in the serumand/orCSF (Calaminus et al. 2005).

Approximately 10% of germinomas may contain

syncytiotrophoblastic elements and secrete b-hCG(Matsutani et al. 1997). Germinomas appear as large

lesions typically slight hyperdense on CT that enhance

after contrast medium administration (FitzPatrick et al.

1999). On MRI, they appear isointense to brain on

T1-weighted images and isointense-slightly hyperintense

on T2-weighted images (Rennert & Doerfler 2007).

Although histological confirmation remains the

‘gold standard’ diagnostic method, the combination

of tumour marker estimation and imaging modalities

can be used in secretory GCT (Packer et al. 2000,

Calaminus et al. 2005). This diagnostic tool is

underscored by the fact that several patients with

parasellar GCT have developed surgical procedure-

related complications (Calaminus et al. 2005). It is

therefore important to avoid aggressive surgical

intervention and develop treatment planning on non-

invasive modalities, and only if in doubt to proceed to a

biopsy (Janmohamed et al. 2002, Calaminus et al.

2005). In cases of non-secretory GCT histological

diagnosis is helpful, but again this may be associated

with considerable morbidity (Packer et al. 2000).

A biopsy can usually be obtained with using

stereotactic neurosurgery or neuroendoscopy;

occasionally, the small tissue fragments obtained can

result in histological specimens that are not represen-

tative of the entire lesion (Packer et al. 2000).

Treatment of GCT involves irradiation to the tumour

bed to obtain local control, craniospinal irradiation to

cover leptomeningeal tumour spread, and chemotherapy

to eliminate leptomeningeal and systemic tumour

dissemination (Gobel et al. 2001). When a pre-operative

diagnosis of a GCT has been obtained, then surgical

exploration is not necessary as these tumours are highly

sensitive to chemotherapy and RT (Gobel et al. 2001,

Janmohamed et al. 2002). Platinum-based chemotherapy

has proven to be highly effective in non-seminomatous

GCT (Allen 1987, Balmaceda et al. 1996) A cumulative

dose of cis-platin of over 300 mg/m2 and tumour

bed irradiation dose of w50–54 Gy, together with

craniospinal irradiation, has a synergistic effect and

achieves a long-term relapse-free survival between 60

and 70% (Janmohamed et al. 2002, Calaminus et al.

2005). Neoadjuvant chemotherapy and delayed

residual tumour resection may be more appropriate



than primary tumour resection followed by the same

chemotherapy (Janmohamed et al. 2002). The presence

of CNS dissemination warrants more aggressive

treatment, such as high-dose chemotherapy with

stem-cell transplantation (Guillamo et al. 2001), or

intraventicular treatment (Osuka et al. 2007). Two recent

studies in children and adults have evaluated long-term

treatment sequelae, revealing mainly impairment of

endocrine function, and rare visual, hearing and

neurological deficits (Legido et al. 1989). In general,

our own approach has been to initiate treatment with

chemotherapy in lesions that appear to be characteristic

of germinomas, even in the absence of positive

tumour markers, and then to re-image several weeks

after initial chemotherapy; rapid shrinkage of the tumour

will usually be confirmatory of the diagnosis, and the

treatment completed.

Primary parasellar lymphomas

Primary CNS lymphomas account for less than 2% of all

intracranial lesions (Fine & Mayer 1993; Fig. 3). By

definition, these tumours are extranodal and arise

primarily in the craniospinal axis, and are distinct from

systemic lymphomas that secondarily metastasise to the

CNS (Megan Ogilvie et al. 2005, Liu et al. 2007).

Although initially described in immunocompromised

patients, a significant increase in the incidence of such

lesions has recently been documented in immunocom-

petent patients (Corn et al. 2000). Lymphomas involving

the sellar/parasellar region are even rarer, representing

less than 1% of all cases in a large cohort of patients who

Figure 3 Coronal enhanced T1-weighted image of lymphoma.There is abnormal dural enhancement of both cavernoussinuses extending to involve the pituitary gland itself and withslight thickening of the stalk.


underwent TSS (Freda & Post 1999). Recently, the

number of primary parasellar lymphomas has substan-

tially increased, the majority being of B-cell origin and

only a minority of T-cell origin; a case of a NK/T-cell

lymphoma has also been reported (Liu et al. 2007).

Approximately 18 patients with sellar/parasellar lym-

phomas have been described with a mean age at

presentation of 55.5 years and male/female ratio of

13:5 (Fine & Mayer 1993, Liu et al. 2007). Endocrine

abnormalities are relatively common, with 72% of

patients exhibiting anterior, and 39% posterior, pituitary

deficiencies respectively (MeganOgilvie et al. 2005, Liu

et al. 2007). In a recent review systemic symptoms, such

as fever of unknown origin, were the presenting

symptoms in 22% of patients, whereas the commonest

presenting compressive symptoms were headache

(56%), diplopia (39%) and visual field defects (28%)

respectively (Liu et al. 2007). MRI may demonstrate

enhancing parasellar masses with diffuse enlargement of

the pituitary (94%), suprasellar extension (44%),

cavernous sinus extension (39%) and stalk thickening

(22%; Liu et al. 2007). Lymphomas usually appear iso-

or hyperdense on CT scanning and isointense on T1-

weighted and slightly hypointense on T2-weighted

images and enhance homogeneously after gadolinium

administration (Buhring et al. 2001). The diagnosis of

primary lymphomas is established histologically and

their treatment includes surgery, chemotherapy and RT

according to established protocols (Megan Ogilvie et al.

2005, Glezer et al. 2008).

Metastases to the parasellar region

Metastases to the parasellar region are relatively rare,

found in less than 1% of patients undergoing TSS for

sellar/parasellar lesions (Komninos et al. 2004).

However, autopsy series have revealed that metastases

to the region comprise between 0.14 and 28.1% of brain

metastases, the most common primaries being breast

and lung cancer in women and men respectively;

however, virtually any neoplasm can metastasise to the

pituitary (Chiang et al. 1990, Sioutos et al. 1996, Megan

Ogilvie et al. 2005). In a significant number of patients,

the parasellar area and the pituitary gland may appear

macroscopically normal besides the presence of metas-

tases that remain clinically non-significant (Ito et al.

2001). Most cases are found in the sixth–seventh decade

of life as part of a generalised metastatic spread,

commonly associatedwithmultiple, particularly osseous

metastases (Chiang et al. 1990, Sioutos et al. 1996).

However, they can occur in young patients, and very

occasionally are the first manifestation of an occult

cancer or the only site of metastasis (Sioutos et al. 1996).

891

Figure 4 Sagittal unenhanced T1-weighted image of acraniopharyngioma. The mass is inseparable from the chiasmand hypothalamus and is predominantly of low T1 signalsuggesting a cystic mass, although without a high lipid content.


Symptomsofmass effect and cranial nerve palsies are the

most frequent symptoms; when metastatic lesions

involve the pituitary gland, hormonal deficiencies,

particularly DI, develop (Sioutos et al. 1996, Komninos

et al. 2004). Although clinically indistinguishable from

other lesions involving the area, specific clinical settings

may point to the diagnosis (Komninos et al. 2004). The

rapidity of development of symptoms of mass effect,

particularly ophthalmoplegia secondary to VI nerve

involvement, in association with the sudden onset of DI

in patients over 50 years, strongly suggests the presence

of metastases irrespective of a history of malignancy

(Ruelle et al. 1992, Sioutos et al. 1996, Morita et al.

1998). Although not specific, radiology can help identify

parasellar metastases in the presence of other brain

metastases and/or rapidly growing lesions; involvement

of the infundibular recess favours a metastatic lesion

(Morita et al. 1998,Komninos et al. 2004). In the absence

of a primary and/or othermetastatic lesions, confirmation

of the diagnosis relies on histology (Chiang et al. 1990).

Treatment is mainly palliative and depends on the

symptoms and the extent of systemic disease (Morita

et al. 1998). Due to the invasive, vascular and

haemorrhagic nature of the lesions, surgical excision is

not usually possible (Sioutos et al. 1996). However,

surgical debulking may offer improvement of symptoms

ofmass effect; this should be followed by local radiation,

systemic chemotherapy and adequate hormonal sub-

stitution. Radiosurgery is sometimes a useful alternative,

particularly for previously irradiated regions, and for

smaller lesions (diameter !30 mm). The overall

prognosis is poor, with a median survival of less than 2

years (Laigle-Donadey et al. 2005).

Supratentorial primitive neuroectodermal tumour is

an embryonal tumour (WHO grade IV) of the cerebrum

or suprasellar region composed of undifferentiated or

poorly differentiated neuroepithelial cells, which have

the capacity for differentiation along neuronal, astro-

cytic, ependymal, muscular or melanocytic lines (Ohba

et al. 2008). Synonyms include cerebral medulloblas-

toma, cerebral neuroblastoma, cerebral ganglioneuro-

blastoma and ‘blue tumour’. This rare tumour occurs

mainly in children with an overall 5-year survival rate

of 34% (Ohba et al. 2008).

Ependymoblastoma is a rare, malignant, embryonal

brain tumour (WHO grade IV) that occurs in neonates

and young children. Ependymoblastomas are often

large and supratentorial and generally relate to the

ventricles, though they can occur in the parasellar

region (Matthay et al. 2003). These types of tumours

grow rapidly, with craniospinal dissemination, and

have a fatal outcome within 6–12 months of diagnosis

(Matthay et al. 2003).

892

Potentially malignant parasellar lesions

Craniopharyngiomas

Craniopharyngiomas are rare epithelial tumours that

arise along the pathway of the craniopharyngeal duct

(Bunin et al. 1998; Figs 4 and 5). They account for

2–5% of all primary intracranial neoplasms and follow

a bimodal age distribution with a peak incidence rate in

children and adults between the ages of 5 and 14 and 50

and 74 years respectively (Bunin et al. 1998). The

majority show a suprasellar component (94–95%), and

may extend into the anterior, middle or posterior fossa

(Petito et al. 1976). Tumours can be solid (1–16%), but

most are cystic or mixed (84–99%); cysts may be

multiloculated and contain liquid that has high content

of membrane lipids and cytokeratins (Karavitaki et al.

2006). Despite their benign histological appearance

(WHO grade I), their infiltrative tendency into critical

parasellar structures and aggressive behaviour, even

after apparently successful treatment, heralds a

significant morbidity and mortality (Karavitaki et al.

2006). Cases of malignant transformation have also

been described, for which the role of previous RT has

not been discounted (Nelson et al. 1988). There are two

primary histological subtypes: the adamantinous and


Figure 5 Sagittal enhanced T1-weighted image of a solidlyenhancing craniopharyngioma. This mass is inseparable fromthe hypothalamus and chiasm. There is an area of low signalwithin the mass representing calcification (confirmed on CT).


the papillary, but transitional or mixed forms have also

been recognised (Zhang et al. 2002). The adamanti-

nous subtype is the most common and bears some

similarity to the adamantinoma of the jaw (Karavitaki

et al. 2006), accounting for the calcification and the

development of teeth encountered particularly in

children (Petito et al. 1976). Adamantinous cranio-

pharyngiomas tend to adhere to the surrounding brain

tissue, often making complete surgical resection

impossible (Petito et al. 1976). The papillary variety,

mostly found in adults, is well circumscribed and

shows less infiltration to adjacent tissues (Karavitaki

et al. 2006). Although, headaches, nausea/vomiting,

papillo-oedema, cranial nerve palsies and hydro-

cephalus are more frequent in children, a large series

found no differences when compared the presenting

manifestations among children and adults (Karavitaki

et al. 2006). Spontaneous rupture of cystic craniophar-

yngioma is rare, but when it occurs can cause chemical

ventriculitis and meningitis (Zee et al. 2003).

Endocrine dysfunction in children manifests as growth

failure in 93% or delayed sexual development in

w20% (Freda & Post 1999). Many adults present with

a variety of anterior pituitary hormone deficiencies and

23% develop DI (Freda & Post 1999). CT is the ideal

modality for the evaluation of the bony anatomy,

identification of calcification and in distinguishing the

solid and cystic components of the tumour (Pusey et al.

1987). Pre- and post-contrast enhanced images identify

the cystic lesions as a non-enhancing areas of low


attenuation; the solid component and the cystic capsule

appear as contrast-enhancing areas (Pusey et al. 1987).

MRI following contrast enhancement offers valuable

topographic and structural analysis (Karavitaki et al.

2006; Table 2). Radical surgery may be successful in

selected tumours; however, when surgical removal was

substantiated with radiological confirmation, complete

removal was accomplished in 18–84% of cases, clearly

a wide range (Hald et al. 1994). Post-operative RT

following either complete or incomplete tumour

removal is associated with significantly decreased

recurrence rate; RT alone provides 10-year recurrence

rates between 0 and 23% (Rajan et al. 1997). Although

the optimum total dose or fractionated protocols have

not been established, it seems that recurrences are

fewer with total doses above 54 Gy (Karavitaki et al.

2006). Recurrent tumours develop at a mean interval

between 1 and 4.3 years, but recurrences as late as 26

years have been described (Coke et al. 1998); such

tumours exhibit higher microvessel density values

(Vidal et al. 2002), and chromosomal aberrations

(Lefranc et al. 2003). Stereotactic radiosurgery is used

for well-defined residual tumour tissue after surgery or

for the treatment of small solid recurrent tumours,

especially after failure of conventional RT (Suh &

Gupta 2006). In large cystic portions, multimodality

approaches with installation of radioisotopes or

bleomycin may provide further benefits (Karavitaki

et al. 2006). Recurring tumours and those that have

undergone malignant transformation have been treated

with systemic chemotherapy and interferon-a, albeitwith short-lived results (Karavitaki et al. 2006).

However, the treatment for aggressive tumours

remains to be assessed by trials including large number

of patients with adequate follow-up. In general, our

own approach has been to attempt surgical removal,

TSS where possible, but not to be radical where this

may in any way compromise the hypothalamus;

this would generally be followed by standard

fractionated RT.

Chordomas and chondrosarcomas

Approximately 10% of non-pituitary parasellar lesions

are cartilaginous, originating from the primitive

notochord in the skull base, chordomas being more

frequent than chondrosarcomas (Allan et al. 2001;

Fig. 6). These are slowly growing tumours presenting

with visual complaints, mainly diplopia, whereas a

third of patients complain of headache (Korten et al.

1998). Less common presentations include dizziness,

tinnitus, facial sensory deficits, ataxia and hemiparesis.

Both tumours are associated with extensive bone

893

Figure 6 Coronal enhanced T1-weighted image of a chon-drosarcoma. This is an enhancing mass involving the left side ofthe sella and the cavernous sinus, but arising from the skullbase just off midline.


destruction (Meyers et al. 1992) but significant

endocrinopathy is unusual, although anterior pituitary

deficiencies may be encountered, particularly with

chordomas (Allan et al. 2001). Following the establish-

ment of clearly defined histopathological criteria, a

distinction can be made as both tumours are positive

for S-100 protein but, unlike chordomas, chondrosar-

comas are negative for cytokeratin markers (CAM 5–2)

and epithelial membrane antigens (Salisbury &

Isaacson 1986). Intracranial chordomas are most

frequently seen around the third decade and in

w10–15% can be intradural (Allan et al. 2001).

Chordomas can reach considerable size at the time of

diagnosis and patients may develop neck pain and

nasopharyngeal obstruction, and some tumours may

progress to malignant transformation (Rennert &

Doerfler 2007). These tumours can extend along the

entire skull base causing destruction of the sella instead

of the ballooning often seen in pituitary adenomas

(Glezer et al. 2008). Bone destruction and calcification

occur in 50% of cases and are better seen on CT; on

MRI they appear heterogeneously hyperintense on T2-

weighted images and show marked contrast enhance-

ment (Rennert & Doerfler 2007).

Less than 200 cases of intracranial chondrosarcomas

have been described (Korten et al. 1998). These

malignant tumours (WHO grades II–III) occur more

commonly in the axial part of the skeleton, represent-

ing less than 5% of skull base tumours with w75%

arising in the parasellar region (Kunanandam &

Gooding 1995). Chondrosarcomas arise off the midline

at the suture line, unlike chordomas that arise from the

894

clivus in the midline. Radiological examination almost

always reveals bone destruction and variable degrees

of calcification on CT, involvement of the neural and

vascular structures on MRI, and mostly hypovascular-

ity on angiography (Korten et al. 1998). Occasionally,

cyst-like hypodense centres secondary to necrosis can

be found (Cohen-Gadol et al. 2003). Although

chondrosarcomas rarely metastasise outside the skull

they tend to have a better 5-year survival rate compared

with chordomas, they expand locally and compress

adjacent structures (Rosenberg et al. 1994). Surgery is

the treatment of choice for both tumours; however, due

to bone invasiveness, total excision is generally not

possible (Glezer et al. 2008). Given the importance of

residual tumour volume as a prognostic indicator,

adjacent therapy is frequently employed (Allan et al.

2001). Standard external RT has been disappointing in

achieving local control although most of the reported

cases refer to chordomas, but radiosurgery may be

more effective (Allan et al. 2001). Although a

sustained response to the combination of ifosfamide

and doxorubicin in a case of recurrent chondrosarcoma

has been described, in most cases chemotherapy fails

(La Rocca et al. 1999).

Haemangiopericytomas

Haemangiopericytomas are rare tumours accounting

for less than 1% of all intracranial tumours (Glezer

et al. 2008, Jalali et al. 2008). Although the majority

are supratentorial, parasagittal or falcine, they can

rarely arise in the sellar/parasellar region with less than

ten cases reported (Jalali et al. 2008). These tumours

are aggressive and highly vascular with numerous

penetrating vessels; although previously considered as

a subtype of angioblastic meningioma, they represent

distinctive mesenchymal neoplasms arising from

pericytes (Stout & Murray 1942). Besides the absence

of firmly established histological criteria for grading

haemangiopericytomas, they appear to correspond to

WHO grades II–III (Kleihues et al. 1993). Most

patients present in middle aged with visual field

defects, headaches and rarely symptoms of endocrine

dysfunction; a case of acromegaly due to a GHRH-

secreting haemangiopericytoma has been described

(Yokota et al. 1985). Surgery followed by RT is the

standard treatment; however, as haemapericytomas are

highly vascular and tend to bleed profusely, it is critical

that the neurosurgeon bases his approach on a

reasonable pre-operative diagnosis (Mena et al. 1991,

Suh & Gupta 2006). Local tumour recurrence

following treatment is common, and late widespread

metastasis can occur (Jalali et al. 2008). In two large



series haemangiopericytomas recurred in 91 and 85%

after 15 years (Mena et al. 1991, Jalali et al. 2008).

Cystic and necrotic areas, haemorrhage and prominent

vascular channels contribute to the heterogeneity in

signal intensity (Zee et al. 2003).

Langerhans’ cell histiocytosis (LCH)

LCH is a rare disease characterised by the clonal

accumulation and/or proliferation of specific dendritic

cells and in this manner represents a neoplastic

disorder (Arceci 1999; Fig. 7). LCH shows a particular

predilection for involvement of the HPS leading to DI

and/or anterior pituitary dysfunction (Arceci 1999,

Makras et al. 2007), but can virtually involve any

organ such as bone, lung, skin, liver, spleen, lymph

nodes and bone marrow (Makras et al. 2007). Making

an early and accurate diagnosis is important as

multisystem LCH is associated with a 20% mortality

rate, and 50% of those who survive develop at least one

permanent consequence (Makras et al. 2007).

Although there is no specific MRI appearance of

HPS–LCH, almost all patients with LCH-induced DI

demonstrate loss of the physiologic intense signal

‘bright spot’ of the posterior pituitary; other common

MRI findings are infundibular enlargement, and/or

the presence of hypothalamic mass lesions (Kaltsas

et al. 2000). In cases where a precise diagnosis cannot

be obtained histological diagnosis from the parasellar

pathology may be required (Kaltsas et al. 2000).

Figure 7 Coronal enhanced T1-weighted image of Langerhans’cell histiocytosis. There is diffuse enlargement and enhance-ment of both cavernous sinuses. The pituitary gland is bulky,although the stalk is not thickened.


The combination of vinblastine with steroids is the

most frequently used initial therapy of LCH involving

the CNS and for multisystem disease (Arico et al.

2003). Although etoposide was initially extensively

used, it is not used any long due to its associated high

risk for the development of leukaemia (Arico et al.

2003). The purine analogue cladribine (2--

chlorodeoxyadenosine, 2-CdA) has been shown to be

effective for patients with recurrent and/or dissemi-

nated disease (Makras et al. 2007). RT, at doses up to

25 Gy, has been used in patients with endocrine

deficiencies and radiological involvement of the

parasellar region with partial or temporary radiological

improvement (Arico et al. 2003).

Mainly benign lesions

Meningiomas

Meningiomas (WHO grade I) are the most common

non-glial primary brain tumour comprising 15% of

primary brain tumours with a peak incidence between

40 and 70 years (Zee et al. 2003; Figs 8 and 9).

Tumours arise from the diaphragma sella, tuberculum

sella, medial lesser wing of sphenoid, anterior clinoid,

clivus cavernous sinus or optic nerve sheath (Smith

2005). In w10–15% of cases, meningiomas arise from

the parasellar region and represent the commonest

tumour of that region after pituitary adenomas; rarely,

they occur entirely within the sella mimicking a

pituitary adenoma (FitzPatrick et al. 1999). There is

a strong association between meningiomas, NF

(multiple tumours) and ionising radiation, depending

on the dose applied (Hartmann et al. 2006). The

clinical presentation is usually with visual disturbance

and occasionally endocrine dysfunction with mildly

raised prolactin levels (Freda & Post 1999). The visual

field defects vary and depend on the location of the

tumour; meningiomas may increase in size during

pregnancy and then become symptomatic (Freda &

Post 1999). Atypical (WHO grade II) meningiomas

may develop in 4–7%, whereas anaplastic tumours

(WHO grade III) are seen in 1–2.8% of cases

(Hartmann et al. 2006). However, malignant

behaviour, although very rare, may occur with any

grade of meningioma (Bruna et al. 2007, Ko et al.

2007). Imaging features of meningiomas frequently

allow pre-operative diagnosis, distinguishing them

from other parasellar tumours (Smith 2005). Lesions

arise from the dura and have a broad attachment to the

dura or fill and expand the cavernous sinus. There may

be a linear, enhancing dural tail extending along the

dura away from the lesion. Bone reaction, with bone

thickening and sclerosis, or expansion of the sphenoid

895

Figure 8 Sagittal enhanced T1-weighted image of a suprasellarmeningioma. The mass lies above the pituitary (which isnormal), involves the chiasm and extends anteriorly along theplanum sphenoidale.


sinus air space, may also be seen (Smith 2005).

Meningiomas typically are similar to grey matter in CT

density and T1- and T2-weighted MR image signal

intensity, enhancing homogeneously and brightly with

occasional areas of diffuse calcification (Smith 2005).

In contrast to other parasellar tumours, meningiomas

encase blood vessels and tend to narrow the lumen

(Young et al. 1988). Surgical excision, particularly in

the presence of symptomatic or growing lesions,

remains the treatment of choice (WHO I). Following

Figure 9 Coronal enhanced T1-weighted image of a menin-gioma in the left cavernous sinus. The meningioma enhancesavidly, expands the cavernous sinus and is causing somenarrowing of the left cavernous carotid artery, which is ofsmaller calibre than the right carotid.

896

surgical excision, grade I tumours recur in 7–20%,

whereas atypical and anaplastic recur in 39–40% and

50–78% respectively (Bruna et al. 2007, Ko et al.

2007, Nakane et al. 2007). Surgery and RT is used in

selected cases, such as for patients with known or

suspected residual disease or with recurrence after

previous surgery, whereas radiation alone is used in

patients with unresectable tumours (Freda & Post

1999, Aghi & Barker 2006). The prognosis is worse for

patients with WHO grades II and III tumours as

complete resection is less common and the prolifera-

tive capacity is greater (Bruna et al. 2007, Ko et al.

2007, Nakane et al. 2007). Malignant histology is

generally associated with a poor prognosis with a

survival less than 2 years (Hartmann et al. 2006, Bruna

et al. 2007, Nakane et al. 2007).

Rathke’s cysts

Rathke’s cleft cysts arise from remnants of squamous

epithelium of Rathke’s pouch and consist of a single

layer of epithelial cells with mucoid, cellular or serous

components in the cyst fluid (Freda & Post 1999;

Fig. 10). Although the majority has a major intrasellar

component, about a third can extend into the parasellar

region; occasionally they can be entirely suprasellar

(Mukherjee et al. 1997, Freda & Post 1999). Many of

these are small and asymptomatic, but they may

become symptomatic due to compressive symptoms

and pituitary hormonal deficiencies, when DI may

develop in up to 20% (Mukherjee et al. 1997). Atypical

presentations include haemorrhages into the cyst and

Figure 10 Sagittal enhanced T1-weighted image of a Rathke’scleft cyst. The cyst is seen to be non-enhancing and lying on thesuperior aspect of the pituitary gland that appears flattened. It iscausing elevation of the optic chiasm.


Figure 11 Sagittal enhanced T1-weighted image of a hypo-thalamic hamartoma. This is seen as a pedunculated masshanging from the undersurface of the hypothalamus. It does notenhance and has the same signal as the grey matter of the brainparenchyma.


abscess formation rarely can coexist with pituitary

adenomas (Mukherjee et al. 1997). They are distin-

guished from craniopharyngiomas histologically by

having walls composed of columnar or cuboidal

epithelium (FitzPatrick et al. 1999). Although no

specific radiological features have been identified,

Rathke’s cysts appear as discrete cystic and non-

enhancing lesions on MRI with variable signal

intensity on either T1- or T2-weighted images; these

lesions need to be differentiated from craniopharyn-

giomas and arachnoid cysts (Mukherjee et al. 1997,

Freda & Post 1999). Treatment involves drainage of

the fluid with or without resection of the cystic wall

(Mukherjee et al. 1997, Freda & Post 1999). Although

these lesions tend not to recur, repeated resections may

be required in as many as a third of patients; it has been

suggested that many relapsing lesions may contain

overlapping histological features with craniopharyn-

giomas (Mukherjee et al. 1997, Freda & Post 1999).

The role of RT for recurrent lesions has not been

clearly defined (Mukherjee et al. 1997).

Epidermoids/dermoids

These benign tumours (WHO grade I) comprise less

than 2% of all intracranial tumours and arise as a result

of incomplete separation of the neuroectoderm from

cutaneous ectoderm (FitzPatrick et al. 1999). Epider-

moids/dermoids occur in the cerebellopontine angle,

pineal region, middle cranial fossa as well as in the

suprasellar region, and consist of tissue of purely

epidermal origin; dermoids also contain tissue of

mesodermal origin (hair follicles, fat, sebaceous

glands). Tumours are cystic structures lined by

keratinised squamous epithelium and the clinical

presentation may be due to local mass effect such as

hydrocephalus, visual disturbance, hypopituitarism, DI

and/or cranial nerve abnormalities (Freda & Post

1999). On CT scan, the cyst contents are very similar

to CSF; both lesions are often hypointense on T1- and

hyperintense on T2-weighted MR images and do not

enhance with contrast. Depending upon fat and

calcium content, dermoid tumours can show a

hyperintense signal in T1 images (Rennert & Doerfler

2007). Diffusion-weighted images can be helpful in

epidermoids, typically showing a markedly increased

signal (Rennert & Doerfler 2007).

Hypothalamic hamartomas

Hypothalamic hamartomas are of neuronal origin and

represent congenital heterotopias usually located

within the tuber cinereum and mostly affecting

children causing precocious puberty and epileptic


seizures (Judge et al. 1977; Fig. 11). As they are

usually less than 2 cm in diameter, they produce few

symptoms of mass effect (Freeman et al. 2004).

Typically, they appear as non-enhancing lesions and

demonstrate rounded expansion of the tuber cinereum,

best seen in coronal and sagittal images; they are

isointense to the cerebral cortex in both T1- and

T2-weighted MR images (Rennert & Doerfler 2007).

Thehamartomas associatedwithprecociouspubertymay

contain GNRH1 neurons, and have been classically

associated with ‘gelastic’ (laughing) seizures.

Paragangliomas

Paragangliomas are rare, usually encapsulated and

benign neoplasms (WHO grade I), that arise in

specialised neural crest cells associated with segmental

or collateral autonomic ganglia (Freeman et al. 2004).

Although the majority develop in the carotid body and

jugular glomus, paraganglionic cells have been demon-

strated in the pituitary gland and adjacent structures

(Steel et al. 1993). Only seven cases of intrasellar, two

cases of suprasellar and four cases of parasellar non-

malignant paragangliomas have been described (Boari

et al. 2006). Tumour location is more relevant than

histology in assessing prognosis; the metastatic rate in

para-aortic paragangliomas ranges between 28 and

42%, whereas only 5% of CNS paragangliomas exhibit

metastatic potential (Boari et al. 2006). Symptoms of

pituitary hormonal deficiency and mass effects are the

897

Figure 13 Coronal enhanced T1-weighted image of a left sidedSchwannoma of the trigeminal nerve. There is an enhancingmass expanding the left cavernous sinus which followed thecourse of the trigeminal nerve on other images.


main presenting symptoms (Steel et al. 1993, Boari

et al. 2006). Surgical excision, when possible, remains

the treatment of choice; there are no data regarding the

prophylactic effect of RT on tumour recurrence.

Lipoma

Lipomas are benign fatty tumours, derived from

remnants of maldevelopment of the primitive meninx

(Smith 2005; Fig. 12). In the sellar region, they occur

as lesions adherent to the surface of the infundibulum,

floor of the third ventricle or adjacent cranial nerves

(Smith 2005). They are usually discovered incidentally

but rarely may enlarge and produce symptoms.

Lipomas are all well-circumscribed, homogeneous

lesions that appear identical to fat on CT and all MRI

sequences, do not enhance and usually exhibit rim

calcification (Smith 2005).

Schwannoma/Neurinoma

Nerve sheath tumours (WHO grade I) in the parasellar

region are very rare and usually arise from the

trigeminal nerve (V1/V2) or the III, IV and VI cranial

nerves (Rennert & Doerfler 2007; Fig. 13). Neurinomas

are slowly growing tumours, rarely causing bony

remodelling of the lateral portion of the sella or the

apex of the petrous bone (Rennert & Doerfler 2007).

Schwannomas are slow-growing tumours that may

erode the walls of cavernous sinus, are found in

associationwithNF2 and exhibit inactivatingmutations

of the NF2 gene in 60% (Aghi & Barker 2006).

They usually develop symptoms of trigeminal nerve

Figure 12 Sagittal unenhanced T1-weighted imageof a suprasellar lipoma. The high signal mass containing fat isseen lying on the undersurface of the hypothalamus in theinterpeduncular cistern.

898

involvement and extremely rarely they can undergo

malignant change (Aghi & Barker 2006). On MRI and

CT, they show an intense (usually heterogeneous)

contrast enhancement (Rennert & Doerfler 2007).

Parasellar granular cell tumours

These are rare tumours originating from either the

neurohypophysis or infundibulum and include

myoblastomas, choristomas and infundibulomas (Cone

et al. 1990, Cohen-Gadol et al. 2003; Fig. 14). In 50% of

cases cause anterior pituitary hormone deficiencies and

hyperprolactinaemia, and rarely visual field defects

(Freda & Post 1999). Although choristomas arise from

the infundibulum and/or posterior lobe, only two cases of

Figure 14 Sagittal enhanced T1-weighted image of a granularcell tumour. This enhancing mass lesion involves the pituitarystalk and the median eminence.



DI have been described; a case presenting with

acromegaly secondary to GHRH secretion has also

been described (Cohen-Gadol et al. 2003). These lesions

are typically isointense to brain, and enhance inhomo-

geneously (Freda & Post 1999). Their firm and vascular

nature, alongwith the lack of an obvious dissection plane

between the tumour and normal brain, prohibits gross

total resection (Cohen-Gadol et al. 2003). Although

radiation therapy has been used, the recurrence rate in

those who underwent RT was not different compared

with those who did not, 4.7 and 5.4 years respectively

(Cohen-Gadol et al. 2003).

Ganglion cell tumours (gangliocytoma)

These are rare tumours that consist of purely neuronal

or mixed adenomatous and neuronal tissue, usually

found in association with a hormonally active pituitary

tumour (Freda & Post 1999). Gangliocytoma (WHO

grade I) and ganglioglioma (WHO grades I–II) are

well-differentiated, slow-growing neuroepithelial

tumours comprised of neoplastic, mature ganglion

cells, either alone (gangliocytoma) or in combination

with neoplastic glial cells (ganglioglioma). Anaplastic

gangliogliomas (WHO grade III) are sometimes seen;

rare cases exhibit WHO grade IV (glioblastoma)

changes in the glial component. The correlation of

anaplasia with clinical outcome is inconsistent (Day

2003, Zee et al. 2003).

Rare parasellar tumours

Ependymomas are glial neoplasms that very rarely can

develop in the parasellar region with only four cases

described up to date; surgery with or without RT is the

treatment of choice (Karim et al. 2006). Pituitocytoma

is a primary tumour of the neurohypophysis, also

located at the pituitary stalk, presenting with headache

and hypopituitarism. Although histologically benign,

the location and vascular nature of the tumour makes

surgical resection difficult (Glezer et al. 2008). Other

tumours such as plasmatocytomas, brown cell tumours

and melanocytic tumours have been described as cases

reports (Glezer et al. 2008).

Non-neoplastic pathologies involving the

parasellar region

A number of non-neoplastic processes can also involve

the parasellar region and present in a similar manner to

parasellar neoplasms (Table 1). Their diagnosis is

usually established in the presence of relevant clinical

settings and if necessary histologically. Abscesses in

the region can develop following direct extension from

the sphenoid sinus, cavernous sinus and CSF or


secondary to bacteraemia; masses of the sella can

become secondarily infected (Freda et al. 1996).

Tuberculosis can produce basilar meningitis and

findings suggestive of a sellar/parasellar mass with

hypopituitarism; there is usually evidence of tubercu-

losis elsewhere (Freda et al. 1996). Fungal, parasitic

and opportunistic infections may also develop particu-

larly in immunocompromised patients (Freda & Post

1999). Sarcoidosis can also present in a similar manner

with varying degrees of hypopituitarism, DI and

cranial neuropathy that in a minority can occur without

evidence of sarcoidosis elsewhere (FitzPatrick et al.

1999). Other granulomatous diseases that can involve

the parasellar region include giant cell granulomatous

hypophysitis, Wegener’s granulomatosis and the

Tolosa–Hunt syndrome (Glezer et al. 2008). Aneur-

ysms originating from the cavernous sinus or circle

of Willis can project into the parasellar region and

their appearance is mostly affected by the amount of

calcification and thrombosis present within the

aneurysms (Zee et al. 2003).

Summary

The parasellar region can be affected by a variety of

tumours. The presentation of these tumours can be

similar to that of large non-functioning pituitary

tumours with extensive extrasellar extension and

other non-neoplastic lesions involving the same region.

Although symptoms of mass effect to adjacent

structures and anterior pituitary endocrine deficits do

not distinguish parasellar tumours from non-function-

ing pituitary tumours, the presence of DI directs

towards a non-pituitary aetiology. Considering the

specific morphological characteristics of MRI and CT,

a presumptive diagnosis is possible in many cases of

parasellar lesions. However, in the majority of cases

their diagnosis involves a multidisciplinary effort

including detailed endocrinological, ophthalmological,

neurological and imaging procedures. In cases of

doubt, a histological diagnosis may still be required to

allow appropriate treatment planning. Treatment

involves a joint effort requiring the collaboration of

different specialties. Although a significant number of

parasellar tumours are slow growing and mostly

benign, it is important to identify those which are

malignant and/or exert a strong malignant potential.

Surgical decompression and/or clearance of the tumour

along with means to prevent recurrence and/or further

tumour growth, such as RT, are usually applied.

Specific hormonal replacement therapy of established

or evolving endocrine deficits is required to maintain

the patient’s quality of life. Primary or adjuvant

899


medical treatment may be necessary for malignant,

recurrent tumours and/or tumours undergoing malig-

nant transformation. Multidisciplinary teams for the

management and support of patients with these

tumours are required for better long-term results.

Tumour-specific therapies are required and need to

be addressed on the basis of tumoral biology. The

central registration of patients seems necessary as it

may provide correlates between forms of treatments

and outcomes and establish prognostic factors at the

pathological or molecular level.

Declaration of interest

These authors declare that there is no conflict of interest that

could be perceived as prejudicing the impartiality of the

research reported.

Funding

This research did not receive any specific grant from any

funding agency in the public, commercial or not-for-profit

sector.

References

Aghi M & Barker FG 2006 Benign adult brain tumors: an

evidence-based medicine review. Progress in Neuro-

logical Surgery 19 80–96.

Allan CA, Kaltsas G, Evanson J, Geddes J, Lowe DG,

Plowman PN & Grossman AB 2001 Pituitary chondro-

sarcoma: an unusual cause of a sellar mass presenting as a

pituitary adenoma. Journal of Clinical Endocrinology and

Metabolism 86 386–391.

Allen JC 1987 Management of primary intracranial germ cell

tumors of childhood. Pediatric Neuroscience 13 152–157.

Allen JC, Kim JH & Packer RJ 1987 Neoadjuvant

chemotherapy for newly diagnosed germ-cell tumors of

the central nervous system. Journal of Neurosurgery 67

65–70.

Arceci RJ 1999 The histiocytoses: the fall of the Tower of

Babel. European Journal of Cancer 35 747–767.

Arico M, Girschikofsky M, Genereau T, Klersy C, McClain

K, Grois N, Emile JF, Lukina E, De Juli E & Danesino C

2003 Langerhans cell histiocytosis in adults. Report from

the International Registry of the Histiocyte Society.

European Journal of Cancer 39 2341–2348.

Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca

JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S

et al. 1996 Chemotherapy without irradiation – a novel

approach for newly diagnosed CNS germ cell tumors:

results of an international cooperative trial. The First

International Central Nervous System Germ Cell Tumor

Study. Journal of Clinical Oncology 14 2908–2915.

900

Baskin DS & Wilson CB 1986 Surgical management of

craniopharyngiomas. A review of 74 cases. Journal of

Neurosurgery 65 22–27.

Black KL & Pikul BK 1999 Gliomas-past, present, and

future. Clinical Neurosurgery 45 160–163.

Boardman JF, Rothfus WE & Dulai HS 2008 Lesions and

pseudolesions of the cavernous sinus and petrous apex.

Otolaryngologic Clinics of North America 41 195–213.

Boari N, Losa M, Mortini P, Snider S, Terreni MR &

Giovanelli M 2006 Intrasellar paraganglioma: a case

report and review of the literature. Acta Neurochirurgica

148 1311–1314.

Brada M & Cruickshank G 1999 Radiosurgery for brain

tumours. BMJ 318 411–412.

Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P & Tortosa A

2007 Ki-67 proliferative index predicts clinical outcome

in patients with atypical or anaplastic meningioma.

Neuropathology 27 114–120.

Buhring U, Herrlinger U, Krings T, Thiex R, Weller M &

Kuker W 2001 MRI features of primary central nervous

system lymphomas at presentation. Neurology 57

393–396.

Bunin GR, Surawicz TS, Witman PA, Preston-Martin S,

Davis F & Bruner JM 1998 The descriptive epidemiology

of craniopharyngioma. Journal of Neurosurgery 89

547–551.

Calaminus G, Bamberg M, Harms D, Jurgens H, Kortmann

RD, Sorensen N, Wiestler OD & Gobel U 2005 AFP/beta-

HCG secreting CNS germ cell tumors: long-term outcome

with respect to initial symptoms and primary tumor

resection. Results of the cooperative trial MAKEI 89.

Neuropediatrics 36 71–77.

Chiang MF, Brock M & Patt S 1990 Pituitary metastases.

Neurochirurgia 33 127–131.

Chong BW & Newton TH 1993 Hypothalamic and pituitary

pathology. Radiologic Clinics of North America 31

1147–1153.

Cohen-Gadol AA, Pichelmann MA, Link MJ, Scheithauer

BW, Krecke KN, Young WF Jr, Hardy J & Giannini C

2003 Granular cell tumor of the sellar and suprasellar

region: clinicopathologic study of 11 cases and literature

review. Mayo Clinic Proceedings 78 567–573.

Coke CC, Corn BW, Werner-Wasik M, Xie Y & Curran WJ

Jr 1998 Atypical and malignant meningiomas: an out-

come report of seventeen cases. Journal of Neuro-

Oncology 39 65–70.

Cone L, Srinivasan M & Romanul FC 1990 Granular cell

tumor (choristoma) of the neurohypophysis: two cases

and a review of the literature. American Journal of

Neuroradiology 11 403–406.

Corn BW, Dolinskas C, Scott C, Donahue B, Schultz C,

Nelson DF & Fisher B 2000 Strong correlation between

imaging response and survival among patients with

primary central nervous system lymphoma: a secondary

analysis of RTOG studies 83-15 and 88-06. International

Journal of Radiation Oncology, Biology, Physics 47

299–303.



Couldwell WT,Weiss MH, Rabb C, Liu JK, Apfelbaum RI &

Fukushima T 2004 Variations on the standard transsphe-

noidal approach to the sellar region, with emphasis on the

extended approaches and parasellar approaches: surgical

experience in 105 cases. Neurosurgery 55 539–547.

Day JD 2003 Surgical approaches to suprasellar and

parasellar tumors. Neurosurgery Clinics of North America

14 109–122.

Fine HA & Mayer RJ 1993 Primary central nervous system

lymphoma. Annals of Internal Medicine 119 1093–1104.

FitzPatrick M, Tartaglino LM, Hollander MD, Zimmerman

RA & Flanders AE 1999 Imaging of sellar and parasellar

pathology. Radiologic Clinics of North America 37

101–121.

Freda PU & Post KD 1999 Differential diagnosis of sellar

masses. Endocrinology and Metabolism Clinics of North

America 28 81–117.

Freda PU, Wardlaw SL & Post KD 1996 Unusual causes of

sellar/parasellar masses in a large transsphenoidal surgical

series. Journal of Clinical Endocrinology and Metabolism

81 3455–3459.

Freeman JL, Coleman LT, Wellard RM, Kean MJ, Rosenfeld

JV, Jackson GD, Berkovic SF & Harvey AS 2004 MR

imaging and spectroscopic study of epileptogenic hypo-

thalamic hamartomas: analysis of 72 cases. American

Journal of Neuroradiology 25 450–462.

Frighetto L, De Salles AA, Behnke E, Smith ZA & Chute D

2003 Image-guided frameless stereotactic biopsy

sampling of parasellar lesions. Technical note. Journal of


Giller CA & Berger BD 2005 New frontiers in radiosurgery

for the brain and body. Proceedings 18 311–319.

Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B,

Shapiro K, Winick N, Mulne AF, Delp JL, Gilio JP et al.

2005 Robotically guided radiosurgery for children.

Pediatric Blood & Cancer 45 304–310.

Glezer A, Paraiba DB & Bronstein MD 2008 Rare sellar

lesions. Endocrinology and Metabolism Clinics of North

America 37 195–211.

Gobel U, Schneider DT, Calaminus G, Jurgens H, Spaar HJ,

Sternschulte W, Waag K & Harms D 2001 Multimodal

treatment of malignant sacrococcygeal germ cell tumors:

a prospective analysis of 66 patients of the German

cooperative protocols MAKEI 83/86 and 89. Journal of

Clinical Oncology 19 1943–1950.

Guillamo JS, Doz F & Delattre JY 2001 Brain stem gliomas.

Current Opinion in Neurology 14 711–715.

Hald JK, Eldevik OP, Brunberg JA & Chandler WF 1994

Craniopharyngiomas – the utility of contrast medium

enhancement for MR imaging at 1.5 T. Acta Radiologica

35 520–525.

Hartmann C, Bostrom J & Simon M 2006 Diagnostic and

molecular pathology of meningiomas. Expert Review of

Neurotherapeutics 6 1671–1683.

Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H,

Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K

et al. 2004 Temozolomide as initial treatment for adults


with low-grade oligodendrogliomas or oligoastrocytomas

and correlation with chromosome 1p deletions. Journal of

Clinical Oncology 22 3133–3138.

Honegger J, Buchfelder M, Fahlbusch R, Daubler B & Dorr

HG 1992 Transsphenoidal microsurgery for craniophar-

yngioma. Surgical Neurology 37 189–196.

Ito I, Ishida T, Hashimoto T, Arita M, Osawa M, Yokota T &

Ishimori T 2001 Hypopituitarism due to pituitary

metastasis of lung cancer: case of a 21-year-old man.

Internal Medicine 40 414–417.

Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr & Laws

ER Jr 2007 Benign brain tumors: sellar/parasellar tumors.

Neurologic Clinics 25 1231–1249.

Jalali R, Srinivas C, Nadkarni TD & Rajasekharan P 2008

Suprasellar haemangiopericytoma – challenges in diag-

nosis and treatment. Acta Neurochirurgica 150 67–71.

Janmohamed S, Grossman AB, Metcalfe K, Lowe DG, Wood

DF, Chew SL, Monson JP, Besser GM & Plowman PN

2002 Suprasellar germ cell tumours: specific problems

and the evolution of optimal management with a

combined chemoradiotherapy regimen. Clinical Endo-

crinology 57 487–500.

Jennings MT, Gelman R & Hochberg F 1985 Intracranial

germ-cell tumors: natural history and pathogenesis.

Journal of Neurosurgery 63 155–167.

Judge DM, Kulin HE, Page R, Santen R & Trapukdi S 1977

Hypothalamic hamartoma: a source of luteinizing-

hormone-releasing factor in precocious puberty. New

England Journal of Medicine 296 7–10.

Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drink-

water JE, Jenkins PJ, Monson JP, Besser GM&Grossman

AB 2000 Hypothalamo-pituitary abnormalities in adult

patients with Langerhans cell histiocytosis: clinical,

endocrinological, and radiological features and response

to treatment. Journal of Clinical Endocrinology and


Karavitaki N, Cudlip S, Adams CB & Wass JA 2006

Craniopharyngiomas. Endocrine Reviews 27 371–397.

Karim M, Sylvia A, Fred G & Patrick S 2006 Ependymoma

of the pituitary fossa. Case report and review of the

literature. Journal of Neurosurgery 105 616–620.

Kitange GJ, Templeton KL & Jenkins RB 2003 Recent

advances in the molecular genetics of primary gliomas.

Current Opinion in Oncology 15 197–203.

Kleihues P, Burger PC & Scheithauer BW 1993 The new

WHO classification of brain tumours. Brain Pathology 3

255–268.

Ko KW, Nam DH, Kong DS, Lee JI, Park K & Kim JH 2007

Relationship between malignant subtypes of meningioma

and clinical outcome. Journal of Clinical Neuroscience

14 747–753.

Komninos J, Vlassopoulou V, Protopapa D, Korfias S,

Kontogeorgos G, Sakas DE & Thalassinos NC 2004

Tumors metastatic to the pituitary gland: case report and

literature review. Journal of Clinical Endocrinology and


901


Korten AG, ter Berg HJ, Spincemaille GH, van der Laan RT

& Van de Wel AM 1998 Intracranial chondrosarcoma:

review of the literature and report of 15 cases. Journal of

Neurology, Neurosurgery, and Psychiatry 65 88–92.

Kunanandam V & Gooding MR 1995 Parasellar chondro-

sarcoma: total excision improves prognosis. British


Laigle-Donadey F, Taillibert S, Martin-Duverneuil N,

Hildebrand J & Delattre JY 2005 Skull-base metastases.

Journal of Neuro-Oncology 75 63–69.

Lamberts SW, de Herder WW & van der Lely AJ 1998

Pituitary insufficiency. Lancet 352 127–134.

Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schuring

MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ,

Salmon I et al. 2003 Characterization of the levels of

expression of retinoic acid receptors, galectin-3,

macrophage migration inhibiting factor, and p53 in

51 adamantinomatous craniopharyngiomas. Journal of


Legido A, Packer RJ, Sutton LN, D’Angio G, Rorke LB,

Bruce DA & Schut L 1989 Suprasellar germinomas in

childhood. A re appraisal. Cancer 63 340–344.

Liu JK, Sayama C, Chin SS & Couldwell WT 2007

Extranodal NK/T-cell lymphoma presenting as a pituitary

mass. Case report and review of the literature. Journal of


Louis DN, Ohgaki H, Wiestler OD, CaveneeWK, Burger PC,

Jouvet A, Scheithauer BW & Kleihues P 2007 The 2007

WHO classification of tumours of the central nervous

system. Acta Neuropathologica 114 97–109.

Maira G, Anile C, Rossi GF & Colosimo C 1995 Surgical

treatment of craniopharyngiomas: an evaluation of the

transsphenoidal and pterional approaches. Neurosurgery

36 715–724.

Makras P, Alexandraki KI, Chrousos GP, Grossman AB &

Kaltsas GA 2007 Endocrine manifestations in Langerhans

cell histiocytosis. Trends in Endocrinology and Metab-

olism 18 252–257.

Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O,

Funata N & Seto T 1997 Primary intracranial germ cell

tumors: a clinical analysis of 153 histologically verified

cases. Journal of Neurosurgery 86 446–455.

Matthay KK, Brisse H, Couanet D, Couturier J, Benard J,

Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D &

Michon J 2003 Central nervous system metastases in

neuroblastoma: radiologic, clinical, and biologic features

in 23 patients. Cancer 98 155–165.

Megan Ogilvie C, Payne S, Evanson J, Lister TA &

Grossman AB 2005 Lymphoma metastasizing to the

pituitary: an unusual presentation of a treatable disease.

Pituitary 8 139–146.

Mena H, Ribas JL, Pezeshkpour GH, Cowan DN & Parisi JE

1991 Hemangiopericytoma of the central nervous system:

a review of 94 cases. Human Pathology 22 84–91.

Meyers SP, Hirsch WL Jr, Curtin HD, Barnes L, Sekhar LN

& Sen C 1992 Chondrosarcomas of the skull base: MR

imaging features. Radiologica 184 103–108.

902

Morita A, Meyer FB & Laws ER Jr 1998 Symptomatic

pituitary metastases. Journal of Neurosurgery 89 69–73.

Mukherjee JJ, Islam N, Kaltsas G, Lowe DG, Charlsworth M,

Afshar F, Trainer PJ, Monson JP, Besser GM&Grossman

AB 1997 Clinical, radiological and pathological features

of patients with Rathke’s cleft cysts: tumors that may

recur. Journal of Clinical Endocrinology and Metabolism

82 2357–2362.

Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S,

Saito K & Yoshida J 2007 Malignant transformation-

related genes in meningiomas: allelic loss on 1p36 and

methylation status of p73 and RASSF1A. Journal of


Nelson GA, Bastian FO, Schlitt M & White RL 1988

Malignant transformation in craniopharyngioma. Neuro-

surgery 22 427–429.

Ohba S, Yoshida K, Hirose Y, Ikeda E & Kawase T 2008

A supratentorial primitive neuroectodermal tumor in an

adult: a case report and review of the literature. Journal of

Neuro-Oncology 86 217–224.

Osuka S, Tsuboi K, Takano S, Ishikawa E, Matsushita A,

Tokuuye K, Akine Y & Matsumura A 2007 Long-term

outcome of patients with intracranial germinoma.


Packer RJ 2000 Chemotherapy: low-grade gliomas of the

hypothalamus and thalamus. Pediatric Neurosurgery 32

259–263.

Packer RJ, Cohen BH & Cooney K 2000 Intracranial germ

cell tumors. Oncologist 5 312–320.

Perks JR, Jalali R, Cosgrove VP, Adams EJ, Shepherd SF,

Warrington AP & Brada M 1999 Optimization of

stereotactically-guided conformal treatment planning of

sellar and parasellar tumors, based on normal brain dose

volume histograms. International Journal of Radiation

Oncology, Biology, Physics 45 507–513.

Petito CK, DeGirolami U & Earle KM 1976 Craniophar-

yngiomas: a clinical and pathological review. Cancer 37

1944–1952.

Pusey E, Kortman KE, Flannigan BD, Tsuruda J & Bradley

WG 1987 MR of craniopharyngiomas: tumor delineation

and characterization. American Journal of Roentgenology

149 383–388.

Rajan B, Ashley S, Thomas DG, Marsh H, Britton J & Brada

M 1997 Craniopharyngioma: improving outcome by early

recognition and treatment of acute complications.

International Journal of Radiation Oncology, Biology,

Physics 37 517–521.

Recinos PF, Sciubba DM & Jallo GI 2007 Brainstem tumors:

where are we today? Pediatric Neurosurgery 43 192–201.

Rennert J & Doerfler A 2007 Imaging of sellar and parasellar

lesions. Clinical Neurology and Neurosurgery 109

111–124.

La Rocca RV, Morgan KW, Paris K & Baeker TR 1999

Recurrent chondrosarcoma of the cranial base: a durable

response to ifosfamide–doxorubicin chemotherapy.




Rosenberg AE, Brown GA, Bhan AK & Lee JM 1994

Chondroid chordoma – a variant of chordoma. A

morphologic and immunohistochemical study. American

Journal of Clinical Pathology 101 36–41.

Ruelle A, Palladino M & Andrioli GC 1992 Pituitary

metastases as presenting lesions of malignancy.

Journal of Neurosurgical Sciences 36 51–54.

Ruscalleda J 2005 Imaging of parasellar lesions. European

Radiology 15 549–559.

Salisbury JR & Isaacson PG 1986 Distinguishing chordoma

from chondrosarcoma by immunohistochemical tech-

niques. Journal of Pathology 148 251–252.

Samandouras G, Kerr RS & Milford CA 2005 Minimally

invasive biopsy of parasellar lesions: safety and clinical

applications of the endoscopic, transnasal approach.

British Journal of Neurosurgery 19 338–344.

Sioutos P, Yen V & Arbit E 1996 Pituitary gland metastases.

Annals of Surgical Oncology 3 94–99.

Smith JK 2005 Parasellar tumors: suprasellar and cavernous

sinuses. Topics inMagnetic Resonance Imaging 16 307–315.

Steel TR, Dailey AT, Born D, Berger MS & Mayberg MR

1993 Paragangliomas of the sellar region: report of two

cases. Neurosurgery 32 844–847.

Stout AP & Murray MR 1942 Hemangiopericytoma: a

vascular tumour featuring Zimmermann’s pericytes.

Annals of Surgery 116 26–33.

Suh JH & Gupta N 2006 Role of radiation therapy and

radiosurgery in the management of craniopharyngiomas.

Neurosurgery Clinics of North America 17 143–148.


Tarbell NJ, Barnes P, Scott RM, Goumnerova L, Pomeroy SL,

Black PM, Sallan SE, Billett A, LaVally B, Helmus A et al.

1994 Advances in radiation therapy for craniopharyngio-

mas. Pediatric Neurosurgery 21 (Supplement 1) 101–107.

Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton

RN, Bates AS, Sheppard MC & Stewart PM 2001

Association between premature mortality and hypopitui-

tarism. West Midlands Prospective Hypopituitary Study

Group. Lancet 357 425–431.

Vidal S, Kovacs K, Lloyd RV, Meyer FB & Scheithauer BW

2002 Angiogenesis in patients with craniopharyngiomas:

correlation with treatment and outcome. Cancer 94

738–745.

Yokota M, Tani E, Maeda Y, Morimura T, Kakudo K &

Uematsu K 1985 Acromegaly associated with suprasellar

and pulmonary hemangiopericytomas. Case report.


Young SC, Grossman RI, Goldberg HI, Spagnoli MV,

Hackney DB, Zimmerman RA & Bilaniuk LT 1988 MR

of vascular encasement in parasellar masses: comparison

with angiography and CT. American Journal of

Neuroradiology 9 35–38.

Zee CS, Go JL, Kim PE, Mitchell D & Ahmadi J 2003

Imaging of the pituitary and parasellar region.

Neurosurgery Clinics of North America 14

55–80.

Zhang YQ, Wang CC & Ma ZY 2002 Pediatric craniophar-

yngiomas: clinicomorphological study of 189 cases.

Pediatric Neurosurgery 36 80–84.

903

The diagnosis and management of parasellar tumours of the pituitary

Documents

Transcript of The diagnosis and management of parasellar tumours of the pituitary